gsk201601046k3.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending January 2016
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 

 
GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc (the Company).
 
On 31 December 2015, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and ADSs in the Company through the annual reinvestment of dividends paid throughout 2015; calculated using an average price of £13.83 per Ordinary Share and $40.98 per ADS:
 
 
Non-Executive Director
Ordinary Shares
No. of ADSs
Sir Philip Hampton
46.839
 
Prof Sir Roy Anderson
1,182.404
 
Dr Stephanie Burns
 
1,036.128
Stacey Cartwright
364.492
 
Lynn Elsenhans
 
542.905
Judy Lewent
 
320.781
Sir Deryck Maughan
 
2,621.255
Dr Daniel Podolsky
 
1,895.600
Urs Rohner
17.420
 
Hans Wijers
175.329
 
 
The Company and the Non-Executive Directors were informed of these allocations on 4 January 2016.
 
This notification relates to transactions notified in accordance with
 
Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
V A Whyte
Company Secretary
 
4 January 2016
 
 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: January 04, 2016 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc